Generic Entry into the Regulated Spanish Pharmaceutical Market

Abstract

This paper empirically analyses entry by generic firms into the strictly regulated Spanish pharmaceutical market. We estimate a fixed effects negative binomial entry model using a panel of 77 active ingredient markets during the period 1999–2005. The results show that generic entry depends positively on revenues, the age of the market, and the number of previous brand-name competitors, and negatively on the number of generic incumbents. We also find that regulation may drive out competition since, contrary to what policy makers might expect, the system of reference pricing restrains generic entry.

This is a preview of subscription content, log in to check access.

References

  1. Allison P. D., Waterman R. P. (2002) Fixed-effects negative binomial regression models. Sociological Methodology 32: 247–265

    Article  Google Scholar 

  2. Aronsson T., Bergman M., Rudholm N. (2001) The impact of generic drug competition on brand name market shares—Evidence from micro data. Review of Industrial Organization 19: 425–435

    Article  Google Scholar 

  3. Bae J. P. (1997) Drug patent expirations and the speed of generic entry. Health Services Research 32: 187–201

    Google Scholar 

  4. Bergman M., Rudholm N. (2003) The relative importance of actual and potential competition: Empirical evidence from the pharmaceuticals market. Journal of Industrial Economics 51: 455–467

    Article  Google Scholar 

  5. Borrell J. R. (2003) Drug price differentials caused by formularies and price caps. International Journal of the Economics of Business 10: 37–50

    Article  Google Scholar 

  6. Borrell J. R., Costas A., Nonell R. (2005) Regulation and competition in the market for pharmaceuticals. In: Puig-Junoy J. (eds) The public financing of pharmaceuticals: An economic approach. Edward Elgar, Cheltenham and Northampton, pp 59–83

    Google Scholar 

  7. Brekke K. R., Königbauer I., Straume O. R. (2007) Reference pricing of pharmaceuticals. Journal of Health Economics 26: 613–642

    Article  Google Scholar 

  8. Cameron A.C., Trivedi P.K. (1998) Regression analysis of count data. Econometric society monograph no. 30. Cambridge University Press, Cambridge

    Google Scholar 

  9. Cameron A. C., Trivedi P. K. (2005) Microeconometrics: Methods and applications. Cambridge University Press, Cambridge

    Google Scholar 

  10. Costa-Font J., Puig-Junoy J. (2005) The pharmaceutical market regulation in Spain: Is drug cost-containment under question. Journal of Pharmaceuticals Finance, Economics and Policy 13: 33–49

    Article  Google Scholar 

  11. Danzon P.M., Chao W.L. (2000) Does regulation drive out competition in pharmaceutical markets?. Journal of Law and Economics 43: 311–357

    Article  Google Scholar 

  12. Danzon, P. M. & Ketcham, J. D. (2004). Reference pricing of pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand. Forum for Health Economics & Policy, 7 (Frontiers in Health Policy Research), Article 2. Retrieved from http://www.bepress.com/fhep/7/2.

  13. Daunfeldt S. O., Rudholm N. (2009) Revenues as a proxy for profits: A cautionary note. Applied Economic Letters 16: 679–681

    Article  Google Scholar 

  14. Daunfeldt S. O., Rudholm N., Bergström F. (2006) Entry into Swedish retail and wholesale trade markets. Review of Industrial Organization 29: 213–225

    Article  Google Scholar 

  15. Ekelund, M. (2001). Generic entry before and after the introduction of reference prices. In M. Ekelund (Ed.), Competition and innovation in the Swedish pharmaceutical market (Chap. 4, pp. 1–17). Dissertation, Stockholm School of Economics.

  16. Ekelund M., Persson B. (2003) Pharmaceutical pricing in a regulated market. Review of Economics and Statistics 85: 298–306

    Article  Google Scholar 

  17. Frank R. G., Salkever D. S. (1997) Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy 6: 75–90

    Article  Google Scholar 

  18. Grabowski H. G., Vernon J. M. (1992) Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 drug act. Journal of Law and Economics 35: 331–350

    Article  Google Scholar 

  19. Hollis A. (2005) How do brands’ ‘own generics’ affect pharmaceutical prices?. Review of Industrial Organization 27: 329–350

    Article  Google Scholar 

  20. Hong S. H., Shepherd M. D., Scoones D., Wan T. T. H. (2005) Product-line extensions and pricing strategies of brand-name drugs facing patent expiration. Journal of Managed Care Pharmacy 11: 746–754

    Google Scholar 

  21. Hudson J. (2000) Generic take-up in the pharmaceutical market following patent expiry: A multi-country study. International Review of Law and Economics 24: 103–112

    Google Scholar 

  22. Iizuka T. (2009) Generic entry in a regulated pharmaceutical market. Japanese Economic Review 60: 63–81

    Article  Google Scholar 

  23. IMS Health. (2006a). Health retail drug monitor: Tracking 13 key global pharma markets. London: IMS Health.

    Google Scholar 

  24. IMS Health. (2006b). Estudio del impacto de los medicamentos genéricos en el mercado español. Madrid: IMS Health.

    Google Scholar 

  25. Königbauer I. (2006) Advertising and generic market entry. Journal of Health Economics 26: 286–305

    Article  Google Scholar 

  26. López-Casasnovas G., Puig-Junoy J. (2000) Review of the literature on reference pricing. Health Policy 54: 87–123

    Article  Google Scholar 

  27. Magazzini L., Pammolli F., Riccaboni M. (2004) Dynamic competition in pharmaceuticals: Patent expiry, generic penetration, and industry structure. European Journal of Health Economics 5: 175–182

    Google Scholar 

  28. Mestre-Ferrándiz J. (1999) The impact of generic goods in the pharmaceutical industry. Health Economics 8: 599–612

    Article  Google Scholar 

  29. Puig-Junoy J. (2004a) Incentives and pharmaceutical reimbursement reforms in Spain. Health Policy 67: 149–165

    Article  Google Scholar 

  30. Puig-Junoy J. (2004b) Los medicamentos genéricos pagan el precio de ser referencia. Revista de Administración Sanitaria 2: 35–59

    Google Scholar 

  31. Puig-Junoy J. (2007) The impact of generic reference pricing interventions in the statin market. Health Policy 84: 14–29

    Article  Google Scholar 

  32. Reiffen D., Ward M. E. (2005) Generic drug industry dynamics. Review of Economics and Statistics 87: 37–49

    Article  Google Scholar 

  33. Reiffen D., Ward M. E. (2007) ‘Branded generics’ as a strategy to limit cannibalization of pharmaceutical markets. Managerial and Decision Economics 28: 251–265

    Article  Google Scholar 

  34. Rudholm N. (2001) Entry and the number of firms in the Swedish pharmaceuticals market. Review of Industrial Organization 19: 351–364

    Article  Google Scholar 

  35. Rudholm N. (2003) Competition and substitutability in the Swedish pharmaceuticals market. Applied Economics 35: 1609–1617

    Article  Google Scholar 

  36. Saha A., Grabowski H., Birnbaum H., Greenberg P. (2006) Generic competition in the US pharmaceutical industry. International Journal of the Economics of Business 13: 15–38

    Article  Google Scholar 

  37. Scott Morton F. (1999) Entry decisions in the generic pharmaceutical industry. RAND Journal of Economics 30: 421–440

    Article  Google Scholar 

  38. Scott Morton F. (2000) Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry. International Journal of Industrial Organization 18: 1085–1104

    Article  Google Scholar 

  39. Segura P. (1997) The peculiar patent and generic situation in Spain. Scrip Magazine 58: 23–25

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Iván Moreno-Torres.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Moreno-Torres, I., Puig-Junoy, J. & Borrell, JR. Generic Entry into the Regulated Spanish Pharmaceutical Market. Rev Ind Organ 34, 373–388 (2009). https://doi.org/10.1007/s11151-009-9214-3

Download citation

Keywords

  • Generic entry
  • Pharmaceutical industry
  • Reference pricing

JEL Classification

  • I11
  • L11
  • L65